Caduceus Capital Partners Names Executive Venture Partners for Second Investment Fund
Caduceus Capital Partners Names Executive Venture Partners for Second Investment Fund
Caduceus Capital Partners, LLC, a venture capital company focused on digital health investments, has named six executive venture partners who will play a key role in the firm’s second fund, Caduceus Capital Partners Early-Stage Digital Health Fund II. These new executive venture partners include:
- Adam Bauer, Vice President, Analytics Services, Optum
- Jon Kaplan, Managing Director and Senior Partner, Boston Consulting Group – Healthcare
- John Johnston, Senior Vice President, Optum Insight
- Russ Rudish, Principal, Rudish Health
- Jeff Sturman, Senior Vice President and Chief Digital Information Officer, Memorial Healthcare System
- Andrew Vaz, Former Managing Partner, Global Ecosystems and Alliances, and Chief Innovation Officer, Deloitte
As active leaders in the investment process, these individuals will source and vet startups, hold director positions on portfolio company boards, support investment fund decisions and advise portfolio company executives.
Caduceus Capital Partners closed Fund I at $29 million in 2023, establishing it among the country’s leading healthcare venture investment companies. Caduceus Capital Partners Early-Stage Digital Health Fund II plans to raise $50 million for investment in 15-20 companies over the next three to five years.
“We have achieved success and solid returns from our first Caduceus Capital Partners fund and are thrilled to launch Fund II with this team of incredible healthcare industry veterans,” said Dave Vreeland, senior managing partner, Caduceus Capital Partners. “Our portfolio companies will benefit from their operational expertise, healthcare sales cycle guidance, market insights and extensive network of potential customers and partners.”
Caduceus Capital Partners has established a distinctive model which focuses exclusively on digital health solutions to expand access, improve patient outcomes, reduce costs, further health equity and enhance the daily working lives of care providers. Caduceus Capital Partners Early-Stage Digital Health Fund II will center on investments in AI-enabled digital health.
“What sets Caduceus Capital Partners apart is our strategy of avoiding passive investments and inflated valuations. We nurture young digital health companies with sensible valuations, led by competent teams,” said Scott Kolesar, managing partner, Caduceus Capital Partners. “With our model, we’re able to make a real impact by securing significant ownership, participating in board memberships and providing extensive support to guide our portfolio companies to the next stage in their journeys.”
About Caduceus Capital Partners, LLC
Caduceus Capital Partners invests in early-stage digital health companies that can make a significant impact on healthcare by expanding access, improving patient outcomes, reducing costs, furthering health equity and enhancing the daily working lives of care providers. The Caduceus Capital Partners investment model actively supports portfolio companies with operational expertise and network access to potential customers and partners. For more information and investment interest, visit www.caduceus.vc.
Katie Schlacter
Schlacter Consulting
Katie@SchlacterConsulting.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508486585/en/
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
Chewy Earnings: Market Likes Repurchase Program and Profit Improvements
-
This 5-Star Stock With a Dividend Yield That Tops 4% Is a Buy
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett
-
DuPont Split Gives Investors Better Choices
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much